Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma

Br J Haematol. 2024 Feb;204(2):e17-e20. doi: 10.1111/bjh.19178. Epub 2023 Oct 31.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols
  • Gemcitabine
  • Hodgkin Disease* / drug therapy
  • Humans
  • Lymphoma, Non-Hodgkin* / drug therapy
  • Neoplasm Recurrence, Local

Substances

  • Gemcitabine
  • pembrolizumab
  • Antibodies, Monoclonal, Humanized